A study on high-dose dexamethasone versus prednisolone as frontline therapy in newly diagnosed immune thrombocytopenia in children
Journal of Hematology and Allied Sciences · 2022
DOI: 10.25259/jhas_12_2021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hematology and Allied Sciences, 2022. Verfasst von Subham Bhattacharya und 5 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
Treatment for children with newly diagnosed immune thrombocytopenia (ITP) includes corticosteroids, out of which prednisolone is commonly used. High-dose dexamethasone (HD-DXM) treatment for children with newly diagnosed ITP can produce better outcomes than prednisone, as stated by many studies. A few articles compare HD-DXM and prednisolone as frontline therapies in newly diagnosed adult ITP but data on pediatric ITP comparing these two drugs are scarce. Material and Methods: It was a randomized, prospective, and cohort study. After enrolment, checking the inclusion and exclusion criteria, each child was randomly distributed into two groups; one cohort was treated with HD-DXM in the dose of 40 mg/m 2 (maximum daily dose 40 mg) for 4 days once every 28 days for three cycles; and one with prednisolone in the dose of 2 mg/kg/day (maximum 60 mg/day) for 2 weeks, with quick tapering. A total of 42 children were enrolled, 21 in each cohort.
Results
The overall response (OR) was 42.9% with HD-DXM therapy. The OR and median time to response were similar in both HD-DXM and prednisolone cohorts. There was also no significant difference in incidences of adverse effects between the two cohorts.
Conclusion
Thus, this study confirms that HD-DXM is a safe, effective, and non-inferior option compared to prednisolone as frontline therapy in newly diagnosed ITP in children.
Zitieren
APA
Bhattacharya, S., Ray, S. S., Chakrabarti, P., Sabui, T., Sadhukhan, S. K., & Bhattacharyya, M. (2022). A study on high-dose dexamethasone versus prednisolone as frontline therapy in newly diagnosed immune thrombocytopenia in children. Journal of Hematology and Allied Sciences. https://doi.org/10.25259/jhas_12_2021
Vancouver
Bhattacharya S, Ray SS, Chakrabarti P, Sabui T, Sadhukhan SK, Bhattacharyya M. A study on high-dose dexamethasone versus prednisolone as frontline therapy in newly diagnosed immune thrombocytopenia in children. Journal of Hematology and Allied Sciences. 2022. doi:10.25259/jhas_12_2021
BibTeX
@article{Bhattacharya2022,
author = {Bhattacharya, Subham and Ray, Siddhartha Sankar and Chakrabarti, Prantar and Sabui, Tapas and Sadhukhan, Sanjoy Kumar and Bhattacharyya, Maitreyee},
title = {A study on high-dose dexamethasone versus prednisolone as frontline therapy in newly diagnosed immune thrombocytopenia in children},
journal = {Journal of Hematology and Allied Sciences},
year = {2022},
doi = {10.25259/jhas_12_2021}
}
EUVIMED